AAPC Certified Professional Coder (CPC) — All Questions

When may an organ- or disease-oriented laboratory panel (for example, a basic metabolic panel) be reported with its panel code?

• a.When any two of the individual component tests within the panel are performed together
• b.Whenever the physician orders it by name, regardless of which tests are run
• c.When at least one component test in the panel is performed, with the rest presumed covered
• d.Only when every component test listed in that panel is performed✓

Panels are all-or-nothing: the panel code may be reported only if ALL of its defined component tests are performed. If only some components are done, you report the individual test codes instead. Reporting a panel when a component was not performed is unbundling in reverse and is inaccurate coding.

A pathologist performs the microscopic examination of a surgical specimen and renders the diagnosis in a written report. This physician work represents which component of the service?

• a.The professional component✓
• b.The global service, which cannot be split
• c.A service that is never separately reportable
• d.The technical component

Surgical pathology, like radiology, can split into technical (specimen accessioning, tissue processing, slide preparation) and professional (the pathologist's microscopic interpretation and diagnostic report) components. The pathologist's interpretive work is the professional component, reported with modifier -26 when the lab bills the technical portion separately.

A clinician orders serial potassium levels drawn several hours apart on the same date to monitor a patient. Which modifier is appended to the repeat laboratory tests?

• a.Modifier -76 (repeat procedure by the same physician)
• b.Modifier -91 (repeat clinical diagnostic laboratory test)✓
• c.Modifier -59 (distinct procedural service)
• d.Modifier -26 (professional component)

Modifier -91 is specific to laboratory tests intentionally repeated on the same day to obtain successive (serial) results — a medically necessary trend, not a re-run of a bad specimen. -76 applies to repeated procedures/services (e.g., imaging), not to clinical lab. Using -91 correctly distinguishes legitimate serial testing from duplicate billing.

Which modifier is appended to certain laboratory tests to indicate they are CLIA-waived tests?

• a.-91 (repeat clinical diagnostic laboratory test)
• b.-59 (distinct procedural service)
• c.-QW (CLIA-waived test)✓
• d.-26 (professional component)

Modifier -QW identifies a test on the CLIA-waived list performed by a facility holding a CLIA certificate of waiver, signaling the lab is authorized to run that simple, low-risk test. -91 is for repeat serial lab tests, -26 for the physician interpretation split, and -59 for unbundling — none of which conveys CLIA-waived status. -QW keeps waived testing compliant.

In molecular pathology, 'Tier 1' codes are best described as:

• a.Gene-specific, analyte-specific molecular procedures, each with its own dedicated code✓
• b.Codes used only for screening panels
• c.Codes that require a pathologist's physical signature to bill
• d.Codes for any laboratory test performed more than once

Tier 1 molecular pathology codes are specific to a named gene/analyte and its defined analysis — each common, well-characterized test gets its own code. Tier 2 codes, by contrast, group less common analyses by level of technical resource/complexity. The tier concept — specific analyte (Tier 1) versus resource-leveled grouping (Tier 2) — is the key distinction, not signatures or repetition.

Surgical pathology codes (organized into ascending service levels) are leveled primarily by:

• a.The type of specimen and the level of physician work/complexity required to examine it✓
• b.The number of days the specimen is stored before examination
• c.Whether the specimen was submitted by a surgeon or a primary-care provider
• d.The patient's age

Surgical pathology levels ascend with the complexity of the specimen and the physician work needed to evaluate it — each level lists the specimens assigned to it. Coding is driven by matching the actual specimen to its designated level, not by storage time, patient age, or who submitted it. Each specimen is generally reported at its own appropriate level.

Modifier -91 (repeat clinical diagnostic laboratory test) is appropriately used when:

• a.The laboratory equipment malfunctioned and the test had to be repeated
• b.The same test is medically necessary to obtain multiple successive (serial) results on the same day✓
• c.A previously known result is simply confirmed with no clinical change
• d.A specimen is re-run because the first result was technically invalid

Modifier -91 is only for tests intentionally repeated on the same day to track a changing clinical picture (serial results — e.g., trending potassium or glucose). It is NOT for re-running a failed specimen, confirming an unchanged result, or fixing an equipment problem — those repeats are not separately billable. Reserving -91 for genuine serial testing prevents duplicate-billing errors.

All components of a basic metabolic panel are performed, plus one additional test that is not part of any panel. How is this reported?

• a.Two panel codes
• b.The panel code for the complete panel, plus the individual code for the additional non-panel test✓
• c.Only the individual component codes, never the panel
• d.Only the panel code; the extra test is bundled into it

Because every component of the panel was performed, the panel code is reported — and the separate, non-panel test is reported additionally with its own code. You do not force a second panel or bury the extra test. Coders must also make sure the extra test is not already a component of the panel, which would be double-counting.

A pathologist performs an intraoperative frozen-section consultation and later examines the permanent sections of the same specimen. How is this reported?

• a.A single combined code that covers both services; when a pathologist performs an intraoperative frozen-section consultation and later reviews the permanent sections, CPT provides one bundled code capturing both efforts, so the frozen section is not separately reportable
• b.The intraoperative consultation (frozen section) is separately reportable in addition to the final surgical pathology examination✓
• c.Only the final surgical pathology code
• d.Only the intraoperative frozen-section code

The intraoperative frozen-section consultation is a distinct service that guides the surgeon in real time, and it is reported in addition to the later routine (permanent-section) surgical pathology examination of the specimen. They are separate work efforts, so both are captured. Reporting only one would undercode the pathologist's contribution.

In drug testing, how do 'presumptive' and 'definitive' codes differ?

• a.Presumptive testing is always more expensive than definitive testing
• b.They are interchangeable and both are routinely reported for the same analyte; presumptive and definitive drug tests describe the same laboratory method, so payers expect both codes on every drug-testing claim to fully document the single result obtained
• c.Definitive testing only screens by drug class
• d.Presumptive testing detects the presence or absence of a drug or drug class; definitive testing identifies the specific drug (and often its quantity)✓

Presumptive (screening) drug tests indicate whether a drug or class is likely present. Definitive tests use more specific methods (e.g., chromatography/mass spectrometry) to identify the exact drug and frequently quantify it. They serve different clinical purposes and are leveled differently; reporting both for the same analyte requires clear medical necessity, not routine stacking.

A routine venipuncture is performed solely to collect a blood specimen for testing. How is the collection reported?

• a.It is always bundled into the laboratory test and is never coded, because the specimen draw is an inseparable part of performing the assay
• b.It is coded as an office/outpatient E/M visit; a routine venipuncture performed solely to draw a specimen is captured under the evaluation and management code for the encounter rather than a distinct collection code, because the draw is part of the visit's clinical work
• c.It is reported separately with the routine venipuncture collection code, in addition to the laboratory test performed✓
• d.It requires modifier -26

The blood-draw (routine venipuncture) is a distinct collection service reported separately from the laboratory analysis it feeds — the lab test code covers the analysis, not the draw. It is not an E/M service, and there is no professional/technical split (-26) for a simple venipuncture. Capturing the collection code appropriately reflects the work of obtaining the specimen.

The choice between a screening and a diagnostic Pap (cervical cytology) is driven by:

• a.The laboratory's location
• b.The patient's insurance
• c.The reason for the test — routine screening of an asymptomatic patient versus follow-up of signs/symptoms or a prior abnormal result — which also affects the diagnosis coding✓
• d.The collection device used — whether a broom, spatula, or endocervical brush is documented — because CPT assigns the screening versus diagnostic Pap code strictly by the specimen-collection instrument recorded, and the clinical reason for obtaining the cytology has no bearing on that code choice

Cervical cytology is classified as screening (routine, asymptomatic patient) or diagnostic (evaluating symptoms or following up a prior abnormal result), and that clinical reason also determines the ICD-10-CM diagnosis sequencing (e.g., a screening Z code versus a sign/symptom or abnormal-finding code). The trap is thinking the lab, device, or payer determines it — the reason for testing does.

A therapeutic drug assay differs from a definitive drug (drug-of-abuse) test in that it:

• a.Is always qualitative only
• b.Measures the concentration of a known, prescribed drug to monitor or adjust therapy, unlike drug-of-abuse testing that screens for or identifies unknown substances✓
• c.Requires no physician order
• d.Is a presumptive screening test that yields only a positive-or-negative class result; therapeutic drug assays are qualitative screens reported from the drug-of-abuse presumptive code family and never produce an actual serum concentration used to titrate a prescribed medication

A therapeutic drug assay (therapeutic drug monitoring) quantifies a known, prescribed medication to keep it within a therapeutic range, whereas presumptive/definitive drug testing screens for or identifies substances of possible abuse. The two serve different clinical purposes and different code families. The trap is treating a therapeutic assay as if it were a drug-screening test.

An organ- or disease-oriented laboratory panel code may be reported only when:

• a.ALL of the tests listed as components of that panel were performed✓
• b.The tests were ordered, whether or not performed
• c.Any one component test was performed
• d.At least half of the component tests listed in the panel were actually performed on the specimen

Panel codes require that every listed component test be performed; if even one is missing, the coder reports the individual tests actually performed instead of the panel. Reporting a panel when components were not all done overstates the service. Choosing the most complete panel that fits avoids fragmenting the claim.

Modifier -90 (reference/outside laboratory) is appended when:

• a.A test is CLIA-waived
• b.The billing provider sends the specimen to an outside laboratory that actually performs the test✓
• c.The specimen is collected by venipuncture
• d.The same laboratory repeats an identical test on the same day to confirm an unexpected initial result

Modifier -90 indicates that laboratory tests were performed by an outside (reference) laboratory but are billed by the treating/referring entity. It is distinct from -91 (a medically necessary REPEAT of the same test on the same day by the same lab) and from CLIA-waived (-QW) designations.

Surgical pathology code level 88300 (the lowest level) describes a specimen that:

• a.Includes immunohistochemical staining
• b.Requires only gross (macroscopic) examination, without microscopic examination✓
• c.Always requires microscopic examination and diagnosis
• d.Involves a frozen-section consultation

The lowest surgical-pathology level (88300) is for specimens needing gross examination only. Higher levels (88302-88309) reflect increasing complexity of the microscopic examination, grouped by specimen type/diagnosis difficulty. Each distinct specimen is coded and counted separately at its appropriate level.

Special stains and immunohistochemistry performed on a surgical-pathology specimen are:

• a.Always included in the surgical-pathology level code
• b.Never separately reportable
• c.Reported only with modifier -90
• d.Reported separately in addition to the surgical-pathology examination code✓

Special stains, histochemical stains, and immunohistochemistry are add-on technical/professional services reported in addition to the base surgical-pathology examination. Codes may be per stain/antibody or per specimen block, and professional/technical components may apply. They capture work beyond the routine H&E microscopic exam.

Cervical/vaginal cytology (Pap) codes are differentiated in part by:

• a.The reporting/screening method — for example, manual screening versus automated (computer-assisted) screening, and the reporting system used✓
• b.The patient's age exclusively
• c.The number of pathologists and cytotechnologists who review the slide before the final cytology result is reported to the ordering clinician for the encounter
• d.The color of the collection swab

Pap test codes distinguish the preparation (conventional smear vs. liquid-based/thin-layer), the screening method (manual, automated/computer-assisted, with or without manual rescreening), and the reporting system (e.g., Bethesda). The clinical indication also separates screening from diagnostic cytology.

In microbiology, a definitive organism identification is reported separately from a culture when:

• a.Only a Gram stain of the primary specimen is performed and reported, which by itself is treated as the complete and definitive identification of the organism
• b.Additional identification procedures (e.g., biochemical or other definitive methods) are needed beyond the primary culture to identify the organism✓
• c.The culture shows no growth
• d.The specimen is discarded

Culture codes may include presumptive identification, while additional definitive identification (biochemical panels, other confirmatory methods) is reported with separate codes when performed. Antimicrobial susceptibility testing is likewise separately reportable. Coders assign each identification/sensitivity step actually performed on the isolate.

Molecular pathology 'Tier 2' codes differ from 'Tier 1' codes in that Tier 2 codes are:

• a.Used only for cytogenetic studies
• b.Specific to a single well-characterized gene or variant each, exactly as the gene-specific Tier 1 molecular codes are defined
• c.Never assigned to molecular testing
• d.Grouped by level of technical resources/complexity and used for lower-volume analyses not assigned a specific Tier 1 code✓

Tier 1 molecular codes are gene/analyte-specific for common, well-defined tests. Tier 2 codes are stratified into levels reflecting the complexity/resources of lower-volume procedures and are used when no specific Tier 1 code exists. Selecting the correct tier and level requires matching the analyte and method.

Flow cytometry services can be separated into:

• a.Only a professional component
• b.A single global flow-cytometry code with no separate technical or professional components reported
• c.A technical component (the cytometric analysis) and a professional interpretation component✓
• d.A surgical-pathology level code

Flow cytometry coding distinguishes the technical work (marker/cell analysis, often per marker or per specified groupings) from the physician's interpretation. Codes are selected by the number of markers and whether interpretation is provided, with professional/technical modifiers applied as appropriate.

A pathology consultation on slides/material prepared and referred from ANOTHER facility is reported with:

• a.A venipuncture code
• b.A consultation-on-referred-material code, distinct from an in-house surgical-pathology examination✓
• c.A routine in-house surgical-pathology level code selected from the standard specimen-examination families
• d.A clinical laboratory panel code

When a pathologist renders a consultation/second opinion on slides or material prepared elsewhere and referred in, a specific consultation code (e.g., for referred slides, with or without additional preparation such as new stains) is used rather than the in-house surgical-pathology examination codes. The type of material and additional work performed guide the selection.

A quantitative laboratory test differs from a qualitative test in that a quantitative test:

• a.Detects only the presence or absence of the analyte, reporting a simple positive or negative result without any numeric concentration value
• b.Is always CLIA-waived
• c.Can never be billed with units
• d.Measures the amount (concentration) of an analyte, whereas a qualitative test reports only its presence or absence✓

Quantitative tests report a numeric amount/concentration of the analyte; qualitative tests report presence/absence; semi-quantitative tests give an approximate range. CPT often has distinct codes for each, so coders must match the code to whether the result is a number, a positive/negative, or a range.

ABO blood typing and Rh(D) typing are generally reported:

• a.Under a single combined transfusion code always
• b.With modifier -91 for each test
• c.As separate codes for each typing service performed✓
• d.Only when a full crossmatch is done

Blood-bank/transfusion-medicine coding provides distinct codes for ABO typing, Rh(D) typing, antibody screens, and crossmatches; each service performed is reported separately per its code and units. Bundling them under one code would understate the work; -91 is reserved for medically necessary repeats of a test.

Modifier -91 (repeat clinical diagnostic laboratory test) is used appropriately when:

• a.The initial specimen was inadequate and rerun
• b.Confirmatory testing is repeated because the analyzer equipment malfunctioned during the first attempted run of the sample
• c.The same test is repeated on the same day to obtain subsequent (serial) medically necessary results✓
• d.A test is sent to an outside reference laboratory

Modifier -91 applies to a medically necessary REPEAT of the same lab test on the same day to track serial values (e.g., serial potassium). It is NOT for reruns due to specimen problems, equipment error, or confirmation of an initial result, and it is not the outside-lab modifier (-90).

Reporting each component of a defined laboratory panel separately (instead of the single panel code) in order to increase reimbursement is an example of:

• a.Unbundling (fragmentation), a compliance/abuse concern✓
• b.A CLIA-waived exception
• c.Standard reference-laboratory billing
• d.Correct use of modifier -91

Billing panel components individually to obtain higher payment than the bundled panel code is 'unbundling'/fragmentation — an improper billing practice that can constitute abuse or fraud. When all components of a panel are performed, the panel code (or the most appropriate combination) must be used per CPT and payer rules.